2 results  1 of 1 

1 Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group
Chyong-Huey Lai, Elizabeth Vallikad, Hao Lin, Lan-Yan Yang, Shih-Ming Jung, Hsueh-Erh Liu, Yu-Che Ou, Hung-Hsueh Chou, Cheng-Tao Lin, Huei-Jean Huang, Kuan-Gen Huang, Jiantai Qiu, Yao-Ching Hung, Tzu-I Wu, Wei-Yang Chang, Kien-Thiam Tan, Chiao-Yun Lin, Angel Chao, Chee-Jen Chang
J Gynecol Oncol.2020;31(1):e5.  Published online 2019 July 26     DOI: http://dx.doi.org/10.3802/jgo.2020.31.e5
      
2 The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience
Young-Jae Lee, Yong-Man Kim, Shin-Wha Lee, Jeong-Yeol Park, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Young-Tak Kim, Joo-Hyun Nam
Obstet Gynecol Sci.2017;60(5):433-439.   Published online 2017 September 18     DOI: http://dx.doi.org/10.5468/ogs.2017.60.5.433
      

 1 of 1